View Document Preview and Link Document Date: 2009-09-22 13:21:02 Open Document File Size: 153,05 KB Share Result on Facebook
Company GE / Spencer SA. / Radiation Therapy Oncology Group / / Country United States / Canada / / Event FDA Phase / / IndustryTerm Treatment of recurrent head and neck cancer / Treatment of Cancer / Cancer Care / therapy for head and neck cancer / radiotherapy equipment / / MedicalCondition cancers / base tongue carcinoma / T4 tumours / T4NOMO glottic cancer / squamous cancers / squamous cell carcinoma / Cancer / oropharyngeal carcinoma / faucial arch squamous cell carcinomas / tumour / carcinoma / neck tumours / T2 epidermoid carcinomas / head tumours / microscopic disease / hypopharyngeal squamous cell cancers / early glottic cancer / T2 glottic cancer / neck cancers / head and neck cancer / squamous cell carcinomas / unacceptable normal tissue injury / head cancers / Nonresectable Squamous Cell Carcinoma / Previously Untreated Oropharyngeal Carcinoma / salivary gland tumours / tumours / / MedicalTreatment radiation therapy / dose fractionation / neck radiotherapy / head radiotherapy / chemotherapy / Radiotherapy / surgery / Brachytherapy / radiation / / Organization European Organization for Research and Treatment of Cancer / Treatment of Cancer / / Person C. Martin M. Haddad / Van Cise / M. Haddad E. Piedbois / / Position selected head / Cancer Care Nova Scotia HEAD / Prime Minister / various head / adjuvant RT / advanced head / recurrent head / physicist / dosimetrist / and radiation technologist / / Product hydroxyurea / fluorouracil / EORTC-22851 / / ProvinceOrState Nova Scotia / / PublishedMedium Current Opinion / Cancer Research / / RadioStation Nova / Syed AM / / Technology radiation / chemotherapy / EORTC protocol / / URL http / SocialTag 
Cancer Care Nova Scotia HEAD AND NECK GUIDELINES Appendix III